Insight

Hagen Kennecke: Possible breakthrough in cancer cachexia with Ponsegromab

Photo of Hagen Kennecke taken from ohsu.edu

Sep 18, 2024, 12:58

Hagen Kennecke: Possible breakthrough in cancer cachexia with Ponsegromab

Hagen Kennecke, Section chief and Chief Health Officer of the OHSU Knight-Legacy Health Cancer Collaborative, shared on X:

“Possible breakthrough in cancer cachexia with Ponsegromab, anti-GDF 15. Significant weight gain, especially in patients with colorectal cancer.”

Ponsegromab for the Treatment of Cancer Cachexia | NEJM

Authors: John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon Lubaczewski, Eric J. Roeland, Tateaki Naito, Andrew E. Hendifar, Marie Fallon, Koichi Takayama, Timothy Asmis, Richard F. Dunne, M.D., Isik Karahanoglu, Carrie A. Northcott, Magdalena A. Harrington, Michelle Rossulek, Ruolun Qiu, Aditi R. Saxena

Hagen Kennecke

Source: Hagen Kennecke/X

Aditi R. Saxena Andrew E. Hendifar cancer cancer cachexia Carrie A. Northcott Eric J. Roeland Hagen Kennecke Isik Karahanoglu Jeffrey Crawford John D. Groarke Koichi Takayama M.D. Magdalena A. Harrington Marie Fallon Michelle Rossulek ocnology OncoDaily Ponsegromab Richard F. Dunne Ruolun Qiu Shannon Lubaczewski Susie M. Collins Tateaki Naito Timothy Asmis

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC